Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Second-line, Single Arm, Phase II Clinical Study With Tremelimumab, a Fully Human Anti-CTLA-4 Monoclonal Antibody as Monotherapy in Patients With Unresectable Malignant Mesothelioma

NCT01649024 is registered in ClinicalTrials.gov with Azienda Ospedaliera Universitaria Senese as lead sponsor.

NCT NCT01649024
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01649024 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Second-line, Single Arm, Phase II Clinical Study With Tremelimumab, a Fully Human Anti-CTLA-4 Monoclonal Antibody as Monotherapy in Patients With Unresectable Malignant Mesothelioma
Lead sponsor
Azienda Ospedaliera Universitaria Senese
Phase
Phase 2
Overall status
Unknown status
Start date
May 31, 2009
Completion date
June 30, 2013
Enrollment
29 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant mesothelioma